National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 13 of 13 Research Studies DisplayedSingh JA, Hossain A, Mudano AS
Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.
The researchers performed a systematic review to compare the benefits and harms of biologics and small molecule tofacitinib versus comparator (methotrexate (MTX) and other disease-modifying antirheumatic drugs) in patients with rheumatoid arthritis (RA) who are naive to methotrexate. They concluded that in MTX-naive RA participants, there was moderate-quality evidence that, compared with MTX alone, biologics with MTX were associated with absolute and relative clinically meaningful benefits in three of the efficacy outcomes.
AHRQ-funded; HS021110.
Citation: Singh JA, Hossain A, Mudano AS .
Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.
Cochrane Database Syst Rev 2017 May 8;5:CD012657. doi: 10.1002/14651858.cd012657.
.
.
Keywords: Comparative Effectiveness, Medication, Arthritis, Patient-Centered Outcomes Research, Evidence-Based Practice
Singh JA, Hossain A, Tanjong Ghogomu E
Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.
This review is focused on biologic or tofacitinib therapy in people with rheumatoid arthritis (RA) who had previously been treated unsuccessfully with biologics. Biologic (with or without methotrexate (MTX)) or tofacitinib (with MTX) use was associated with clinically meaningful and statistically significant benefits compared to placebo or an active comparator (MTX/other traditional disease-modifying anti-rheumatic drugs) among people with RA previously unsuccessfully treated with biologics.
AHRQ-funded; HS021110.
Citation: Singh JA, Hossain A, Tanjong Ghogomu E .
Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.
Cochrane Database Syst Rev 2017 Mar 10;3:CD012591. doi: 10.1002/14651858.cd012591.
.
.
Keywords: Comparative Effectiveness, Medication, Arthritis, Patient-Centered Outcomes Research, Evidence-Based Practice
Charles-Schoeman C, Yin Lee Y, Shahbazian A
Improvement of high-density lipoprotein function in patients with early rheumatoid arthritis treated with methotrexate monotherapy or combination therapies in a randomized controlled trial.
This study was undertaken to evaluate changes in HDL function and HDL-associated proteins over 2 years of follow-up in patients with early rheumatoid arthritis receiving either methotrexate (MTX) monotherapy, MTX + etanercept (ETN) combination therapy, or MTX + sulfasalazine (SSZ) + hydroxychloroquine (HCQ) triple therapy. It found that reduced disease activity in patients with any of the 3 therapies in the trial was associated with improvements in the HDL function profile.
AHRQ-funded; HS018517.
Citation: Charles-Schoeman C, Yin Lee Y, Shahbazian A .
Improvement of high-density lipoprotein function in patients with early rheumatoid arthritis treated with methotrexate monotherapy or combination therapies in a randomized controlled trial.
Arthritis Rheumatol 2017 Jan;69(1):46-57. doi: 10.1002/art.39833.
.
.
Keywords: Arthritis, Medication, Comparative Effectiveness
Herrinton LJ, Harrold L, Salman C
Population variations in rheumatoid arthritis treatment and outcomes, Northern California, 1998-2009.
This study assessed variations in rheumatoid arthritis treatment and outcomes at the community level from 1998 through 2009. It found that disease-modifying anti-rheumatic drug use increased in the typical patient from 38 to 63 percent of the time, and oral prednisone use declined from 23 to 15 percent of the time, whereas opioid use initially rose but then fell to 23 percent of the time.
AHRQ-funded; HS019912; HS010391; HS021590; HS018517; HS017919.
Citation: Herrinton LJ, Harrold L, Salman C .
Population variations in rheumatoid arthritis treatment and outcomes, Northern California, 1998-2009.
Perm J 2016 Winter;20(1):4-12. doi: 10.7812/tpp/15-028.
.
.
Keywords: Arthritis, Medication, Comparative Effectiveness, Outcomes
Curtis JR, Sarsour K, Napalkov P
Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor alpha agents, a retrospective cohort study.
Interstitial lung disease (ILD) is a common extra-articular condition in rheumatoid arthritis (RA), but few studies have systematically investigated its incidence and risk factors in patients receiving anti-tumor necrosis factor-alpha (anti-TNFα) agents or alternate mechanisms of action (MOAs). After examining 13,795 episodes of biologic exposure in 11,219 patients, researchers found no significant differences in the risk of ILD and its related complications between RA patients receiving anti-TNFα agents and those receiving alternate MOA agents.
AHRQ-funded; HS018517.
Citation: Curtis JR, Sarsour K, Napalkov P .
Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor alpha agents, a retrospective cohort study.
Arthritis Res Ther 2015 Nov 11;17:319. doi: 10.1186/s13075-015-0835-7..
Keywords: Arthritis, Comparative Effectiveness, Medication, Respiratory Conditions, Risk
Bannuru RR, McAlindon TE, Sullivan MC
Effectiveness and implications of alternative placebo treatments: a systematic review and network meta-analysis of osteoarthritis trials.
The researchers evaluated the effects of alternative placebo types on pain outcomes in knee osteoarthritis. Their review concluded that all placebos are not equal, and some can trigger clinically relevant responses. Differential placebo effects can substantially alter estimates of the relative efficacies of active treatments.
AHRQ-funded; HS021396.
Citation: Bannuru RR, McAlindon TE, Sullivan MC .
Effectiveness and implications of alternative placebo treatments: a systematic review and network meta-analysis of osteoarthritis trials.
Ann Intern Med 2015 Sep 1;163(5):365-72. doi: 10.7326/m15-0623..
Keywords: Comparative Effectiveness, Arthritis, Medication, Pain, Outcomes
Bannuru RR, McAlindon TE, Sullivan MC
Effectiveness and implications of alternative placebo treatments: a systematic review and network meta-analysis of osteoarthritis trials.
The researchers evaluated the effects of alternative placebo types on pain outcomes in knee osteoarthritis. Their review concluded that all placebos are not equal, and some can trigger clinically relevant responses. Differential placebo effects can substantially alter estimates of the relative efficacies of active treatments.
AHRQ-funded; HS021396.
Citation: Bannuru RR, McAlindon TE, Sullivan MC .
Effectiveness and implications of alternative placebo treatments: a systematic review and network meta-analysis of osteoarthritis trials.
Ann Intern Med 2015 Sep 1;163(5):365-72. doi: 10.7326/m15-0623..
Keywords: Comparative Effectiveness, Arthritis, Medication, Pain, Outcomes
Singh JA, Cameron C, Noorbaloochi S
Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis.
The researchers sought to determine whether biological drugs are associated with an increased risk of serious infection compared with traditional disease-modifying antirheumatic drugs (DMARDs). They found that standard-dose and high-dose biological drugs, with or without traditional DMARDs, are associated with an increase in serious infections in rheumatoid arthritis compared with traditional DMARDs, although low-dose biological drugs are not.
AHRQ-funded; HS021110.
Citation: Singh JA, Cameron C, Noorbaloochi S .
Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis.
Lancet 2015 Jul 18;386(9990):258-65. doi: 10.1016/s0140-6736(14)61704-9.
.
.
Keywords: Comparative Effectiveness, Medication, Arthritis, Patient-Centered Outcomes Research
Harrold LR, Reed GW, Kremer JM
The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor.
The investigators compared the effectiveness of abatacept (ABA) versus a subsequent anti-tumour necrosis factor inhibitor (anti-TNF) in rheumatoid arthritis (RA) patients with prior anti-TNF use. They found that RA patients with prior anti-TNF exposures had similar outcomes if they switched to a new anti-TNF as compared with initiation of ABA.
AHRQ-funded; HS018517.
Citation: Harrold LR, Reed GW, Kremer JM .
The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor.
Ann Rheum Dis 2015 Feb;74(2):430-6. doi: 10.1136/annrheumdis-2013-203936.
.
.
Keywords: Comparative Effectiveness, Medication, Patient-Centered Outcomes Research, Arthritis
Bannuru RR, Schmid CH, Kent DM
Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis.
To determine the relative efficacy of the primary knee osteoarthritis (OA) treatments, the researchers performed a comprehensive review of the literature, using a network meta-analysis design. Their comparison of seven different medications found that intra-articular (IA) treatments (IA corticosteroids, IA hyaluronic acid) were superior to non-steroidal anti-inflammatory drugs.
AHRQ-funded; HS021396; HS018574
Citation: Bannuru RR, Schmid CH, Kent DM .
Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis.
Ann Intern Med. 2015 Jan 6;162(1):46-54. doi: 10.7326/M14-1231..
Keywords: Comparative Effectiveness, Medication, Arthritis, Outcomes, Pain
Baddley JW, Winthrop KL, Chen L
Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study.
The purpose of this paper was to determine, among patients with autoimmune diseases in the USA, whether the risk of non-viral opportunistic infections (OI) was increased among new users of tumour necrosis factor alpha inhibitors (TNFI), when compared to users of non-biological agents used for active disease. The investigators concluded that in the USA, the rate of non-viral OI was higher among new users of TNFI with autoimmune diseases compared to non-biological disease-modifying antirheumatic drugs users.
AHRQ-funded; HS017552; HS018517; HS017919.
Citation: Baddley JW, Winthrop KL, Chen L .
Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study.
Ann Rheum Dis 2014 Nov;73(11):1942-8. doi: 10.1136/annrheumdis-2013-203407..
Keywords: Arthritis, Comparative Effectiveness, Medication, Patient Safety
Curtis JR, Zhang J, Xie F
Use of oral and subcutaneous methotrexate in rheumatoid arthritis patients in the United States.
The researchers aimed to examine the epidemiology of methotrexate (MTX) use among rheumatoid arthritis patients initiating MTX, including dosing, method of administration (oral versus subcutaneous (SC)) , and persistence. They also compare the effectiveness of 2 strategies in regard to delaying or avoiding use of biologic agents: switching to SC MTX or adding another nonbiologic disease-modifying antirheumatic drug.
AHRQ-funded; HS018517
Citation: Curtis JR, Zhang J, Xie F .
Use of oral and subcutaneous methotrexate in rheumatoid arthritis patients in the United States.
Arthritis Care Res. 2014 Nov;66(11):1604-11. doi: 10.1002/acr.22383..
Keywords: Arthritis, Comparative Effectiveness, Medication
Navarro-Millán I, Sattui SE, Curtis JR
Systematic review of tumor necrosis factor inhibitor discontinuation studies in rheumatoid arthritis.
The objective of this article is to conduct a systematic review of the available literature on discontinuation of anti-tumor necrosis factor (anti-TNF) agents in rheumatoid arthritis (RA) patients and the associated features of study designs, including eligibility criteria, outcome definitions, and outcomes of discontinuation. The authors concluded that discontinuation of anti-TNF therapy is achievable for many RA patients who start in clinical remission or low disease activity.
AHRQ-funded; HS018517
Citation: Navarro-Millán I, Sattui SE, Curtis JR .
Systematic review of tumor necrosis factor inhibitor discontinuation studies in rheumatoid arthritis.
Clin Ther. 2013 Nov;35(11):1850-61.e1. doi: 10.1016/j.clinthera.2013.09.015..
Keywords: Comparative Effectiveness, Outcomes, Arthritis, Medication, Chronic Conditions